|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02096 SIMCERE PHARMA
Nominal 
6.780 +0.140 (+2.108%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 3,113,524 | -7.930% | 3,381,695 | 2,699,650 | 2,120,002 | 1,925,413 |
| Cost of Sales | (651,592) | -20.572% | (820,358) | (557,371) | (456,977) | (388,130) |
| Gross Profit | 2,461,932 | -3.881% | 2,561,337 | 2,142,279 | 1,663,025 | 1,537,283 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 591 | 50.382% | 393 | (334) | (14,884) | (4,393) | |
| Profit / (Loss) before Taxation | 494,693 | -78.716% | 2,324,219 | 52,523 | 521,840 | 224,733 | |
| Taxation | (38,093) | -25.811% | (51,346) | 9,398 | 33,055 | (39,898) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 811 | 1,863 | 2,919 | 683 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 456,600 | -79.918% | 2,273,684 | 63,784 | 557,814 | 185,518 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,942) | -84.804% | (12,780) | (11,746) | 19,382 | 68,725 |
| Depreciation & Amortisation | 161,248 | 7.067% | 150,605 | 134,150 | 131,022 | 105,985 |
| Directors' Emoluments | -- | -- | -- | -- | -- | 10,811 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 18.000 | -79.310% | 87.000 | 2.000 | 21.000 | 8.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 2.716 | -- | 3.398 | 2.315 | 2.163 | -- |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 456,600 |
| %Change | -79.918% |
| EPS / (LPS) | RMB 0.180 |
| NBV Per Share (¥) | RMB 2.716 |